FOLH1 positive

P1/2, N=140, Completed, Universitair Ziekenhuis Gent | Active, not recruiting --> Completed

Key advances include: (1) In bladder cancer, perioperative durvalumab (NIAGARA) and enfortumab vedotin plus pembrolizumab (KEYNOTE-905/EV-303) set new standards, while HER2-targeted disitamab vedotin plus toripalimab (RC48-C016) improved metastatic survival...(3) In prostate cancer, enzalutamide plus leuprolide improved survival in high-risk biochemical recurrence (EMBARK). Capivasertib plus abiraterone benefited PTEN-deficient metastatic hormone-sensitive disease (CAPItello-281). The PSMAddition trial demonstrated that adding [177Lu]Lu-PSMA-617 to standard therapy significantly improved radiographic PFS in PSMA-positive mHSPC. Docetaxel scheduling was optimized (ARASAFE), and an AI model (STAMPEDE) identified patients for AR inhibitor benefit. Novel agents like saruparib and pasritamig showed promise...The 2025 evidence establishes multiple new standards of care across GU cancers, emphasizing biomarker-driven strategies, immunotherapy integration, novel resistance mechanisms, and treatment optimization. This synthesis provides an evidence-based framework for updating guidelines and highlights the move toward more personalized management, while noting persistent challenges and future research needs.

Notably, nearly two-thirds of identified CTCs were EpCAM-negative but PSMA positive (a prostate specific epithelial marker), suggesting that traditional use of EpCAM as an epithelial marker for CTCs may lead to false negatives. These findings highlight the potential of DHM for applications including but not limited to screening, diagnostics, and precision oncology.

P2, N=40, Suspended, M.D. Anderson Cancer Center | Initiation date: Dec 2025 --> Aug 2025 | Recruiting --> Suspended

P1, N=6, Active, not recruiting, C Ray Therapeutics | Recruiting --> Active, not recruiting

P1, N=24, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Mar 2026 --> Oct 2026

P2, N=110, Active, not recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jul 2026 --> Dec 2026 | Recruiting --> Active, not recruiting

P1, N=198, Recruiting, Bayer | N=73 --> 198 | Trial completion date: May 2031 --> May 2032 | Trial primary completion date: Jun 2027 --> Nov 2028

Our results suggest that PSMA could be used as a biomarker in BC, given that it is highly expressed in more aggressive tumors. These findings open the way to a clinical investigation for the possible use of PSMA as a theranostic biomarker in BC patients with PSMA positive PET scan.

P=N/A, N=753, Not yet recruiting, Novartis Pharmaceuticals

While [¹⁸F]PSMA 1007 PET/CT remains superior for overall lesion detection, [¹⁸F]FAPI 42 PET/CT may provide complementary value in selected scenarios, particularly in subsets with reduced PSMA expression.

P2, N=12, Recruiting, H. Lee Moffitt Cancer Center and Research Institute